Tag Archives: ViiV

August, 2018

16 August
Janssen Reports Positive Topline Results for Phase 3 Study of Long Acting Injectable Two-Drug Regimen for Treatment of HIV

CORK, Ireland, Aug. 15, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today confirmed positive topline results from the global, Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) study of the first investigational long-acting injectable two-drug regimen (2DR) for the treatment of HIV-1. The ATLAS study results …
Share

26 July
Studies Show Two-Drug Regimen of Dolutegravir and Lamivudine Has Similar Efficacy to a Three-Drug Regimen in Treatment Naïve HIV Patients

LONDON–(BUSINESS WIRE)–ViiV Healthcare today presented at the 22nd International AIDS conference in Amsterdam 48-week results from the phase III GEMINI 1 & 2 studies, assessing the safety and efficacy of a two-drug regimen (2DR) of dolutegravir (DTG) and lamivudine (3TC) compared to a three-drug regimen of dolutegravir and two nucleoside …
Share

10 June
ViiV Announces FDA Approval to Lower the Weight Limit for Dolutegravir in Children with HIV

LONDON, June 10, 2016 /PRNewswire/ — Reduction of weight limit to at least 30kg means more children and adolescents will be eligible for dolutegravir ViiV Healthcare today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral …
Share

4 November
ViiV Announces Positive Mid-Stage Results for its HIV Therapy

London, UK, 3 November 2015 – ViiV Healthcare, a global specialist HIV company with GSK, Pfizer Inc. and Shionogi Limited as shareholders, today announced that the Phase IIb study LATTE 2 (NCT02120352) met its primary endpoint at 32 weeks. These results show that the investigational, long acting, injectable formulations of …
Share